World Journal of Endocrine Surgery

Register      Login

VOLUME 10 , ISSUE 3 ( September-December, 2018 ) > List of Articles

ORIGINAL ARTICLE

Clinical Staging Variability and Surgery in Papillary Thyroid Cancers with Tumor Size 1 to 4 cm

Brielle E Wood, James T Williams, Bruce G Ashford, Steven J Craig

Keywords : Cohort study, High-risk features, Papillary thyroid cancer, Staging, Surgery, Thyroid nodule

Citation Information : Wood BE, Williams JT, Ashford BG, Craig SJ. Clinical Staging Variability and Surgery in Papillary Thyroid Cancers with Tumor Size 1 to 4 cm. World J Endoc Surg 2018; 10 (3):149-153.

DOI: 10.5005/jp-journals-10002-1237

License: CC BY-NC 4.0

Published Online: 01-12-2018

Copyright Statement:  Copyright © 2018 Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim: Recent guidelines have attempted to de-escalate treatment pathways for low-risk papillary thyroid carcinoma (PTC) to reduce long-term morbidities associated with treatment. The literature supporting either hemithyroidectomy or total thyroidectomy for PTC between 1 and 4 cm is conflicting and dependent on the accuracy of clinical staging. We examined the variability between clinical and pathological tumor staging for PTC 1 to 4 cm. Materials and methods: This study is a single center, retrospective cohort study of all patients who underwent surgery for confirmed PTC between 1 and 4 cm, from January 2010 to August 2017. Results: The cohort included 38 patients, of which 20 patients (53%) had no high-risk features on histopathology, and 18 patients (47%) had one or more high-risk feature. Fiftyfive percent of patients had a 5mm or more variance between preoperative and postoperative sizing. Among the patients with no high-risk features, preoperative ultrasound overestimated the size (p = 0.0007) and stage (55% downgraded) when compared to postoperative histopathology reports. 80% of patients that underwent hemithyroidectomy had no high-risk features and avoided completion thyroidectomy. Conclusion: We identified a particular cohort of patients that had no high-risk features on final histopathology that had greater differences in preoperative and postoperative tumor sizes. Overestimation of size and stage of PTC has the potential for the overtreatment of these patients. This study has shown the importance of determining high-risk features and other PTC parameters, such as size and staging. We have highlighted the potential importance of preoperative or intraoperative tumor evaluation in identifying patients who could benefit from conservative surgical approaches. Clinical significance: Identification of papillary thyroid cancer patients without high-risk features either preoperatively or intraoperatively can provide surgeons with a stratified guideline to decide which patients are suitable for conservative surgery compared to total thyroidectomy.


PDF Share
  1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006 May; 295:2164-2167.
  2. Abdelgadir Adam M, Pura J, Goffredo P, Dinan MA, Hyslop T, Reed SD, et al. Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years. The Journal of Clinical Endocrinology & Metabolism. 2015 Jan 1;100(1):115-121.
  3. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA: a cancer journal for clinicians. 2012 Jul;62(4):220-241.
  4. Aschebrook-Kilfoy B, Schechter RB, Shih YC, Kaplan EL, Chiu BC, Angelos P, et al. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiology and Prevention Biomarkers. 2013 May 15.
  5. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014 Apr; 140:317-322.
  6. Haugen Bryan R, Alexander Erik K, Bible Keith C, Doherty- Gerard M, Mandel Susan J, Nikiforov Yuri E, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 Jan 12.
  7. Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014 Jul;81 Suppl 1:1-122.
  8. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. Extent of surgery affects survival for papillary thyroid cancer. Annals of surgery. 2007 Sep;246(3):375- 381.
  9. Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014 Oct;260(4):601-605; discussion 605-607.
  10. Matsuzu K, Sugino K, Masudo K, Nagahama M, Kitagawa W, Shibuya H, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World journal of surgery. 2014 Jan 1;38(1):68-79.
  11. Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg 2010 Nov; 136:1055-1061.
  12. Kuba S, Yamanouchi K, Hayashida N, Maeda S, Adachi T, Sakimura C, et al. Total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer: Comparative analysis after propensity score matching: A multicenter study. International Journal of Surgery. 2017 Feb 1;38:143-148.
  13. Varaldo E, Ansaldo GL, Assalino M, Massobrio A, Torre GC, Borgonovo G. Completion thyroidectomy for differentiated thyroid cancer (results in a consecutive series of 68 patients). Acta Chir Belg 2012 Jan; 112:40-43.
  14. Donatini G, Castagnet M, Desurmont T, Rudolph N, Othman D, Kraimps JL. Partial Thyroidectomy for Papillary Thyroid Microcarcinoma: Is Completion Total Thyroidectomy Indicated? World J Surg 2016 Mar; 40:510-515.
  15. Kwon H, Jeon MJ, Kim WG, Park S, Kim M, Song DE, et al. A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: a retrospective individual risk factor-matched cohort study. Eur J Endocrinol. 2017 Apr;176(4):371-378.
  16. Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? Cancer 2017 Feb; 123:372-381.
  17. Lang BH, Shek TW, Wan KY. The significance of unrecognized histological high-risk features in response to therapy in papillary thyroid carcinoma measuring 1-4 cm: implications for completion thyroidectomy following lobectomy. Clin Endocrinol (Oxf) 2017 Feb; 86:236-242.
  18. Haymart MR, Greenblatt DY, Elson DF, Chen H. The role of the intraoperative frozen section if suspicious for papillary thyroid cancer. Thyroid 2008 Apr; 18:419-423.
  19. Lumachi F, Borsato S, Tregnaghi A, Marino F, Polistina F, Basso SM, et al. FNA cytology and frozen section examination in patients with follicular lesions of the thyroid gland. Anticancer research. 2009 Dec 1;29(12):5255-5257.
  20. Hong JC, Seo JW, Jang AL, Suh SH, Pak MG, Han SH, et al. The utility of intra-operative frozen section for the evaluation of microscopic extrathyroidal extension in papillary thyroid carcinoma. Clinical Otolaryngology. 2017 Dec;42(6):1167-1171.
  21. Estebe S, Montenat C, Tremoureux A, Rousseau C, Bouilloud F, Jegoux F. Limitation of the intraoperative frozen section during thyroid surgery. Eur Arch Otorhinolaryngol 2017 Mar; 274:1671-1676.
  22. Shaha AR, Shah JP, Loree TR. Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol 1997 Jun; 4:328-333.
  23. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998 Dec; 83:2638-2648.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.